225 related articles for article (PubMed ID: 29205808)
1. Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy.
Zhao N; Zeng Z; Zu Y
Small; 2018 Jan; 14(4):. PubMed ID: 29205808
[TBL] [Abstract][Full Text] [Related]
2. pH-responsive DNA nanomicelles for chemo-gene synergetic therapy of anaplastic large cell lymphoma.
Li Y; Yue S; Cao J; Zhu C; Wang Y; Hai X; Song W; Bi S
Theranostics; 2020; 10(18):8250-8263. PubMed ID: 32724469
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Treatment of Tumor by Targeted Biotherapy and Chemotherapy via Site-Specific Anchoring of Aptamers on DNA Nanotubes.
Chen R; Sun P; Chu X; Pu X; Yang Y; Zhang N; Zhao Y
Int J Nanomedicine; 2020; 15():1309-1320. PubMed ID: 32161460
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-Equipped Protamine Nanomedicine for Precision Lymphoma Therapy.
Zeng Z; Tung CH; Zu Y
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218299
[TBL] [Abstract][Full Text] [Related]
5. A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma.
Zhao N; Bagaria HG; Wong MS; Zu Y
J Nanobiotechnology; 2011 Jan; 9():2. PubMed ID: 21281497
[TBL] [Abstract][Full Text] [Related]
6. Self-assembly of DNA nanostructure containing cell-specific aptamer as a precise drug delivery system for cancer therapy in non-small cell lung cancer.
Wang N; Yu C; Xu T; Yao D; Zhu L; Shen Z; Huang X
J Nanobiotechnology; 2022 Nov; 20(1):486. PubMed ID: 36403038
[TBL] [Abstract][Full Text] [Related]
7. CD30 aptamer-functionalized PEG-PLGA nanoparticles for the superior delivery of doxorubicin to anaplastic large cell lymphoma cells.
Luo X; Yang Y; Kong F; Zhang L; Wei K
Int J Pharm; 2019 Jun; 564():340-349. PubMed ID: 31002934
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy of Colon Cancer by Aptamer-Guided Holliday Junctions Loaded with Doxorubicin.
Yao F; An Y; Li X; Li Z; Duan J; Yang XD
Int J Nanomedicine; 2020; 15():2119-2129. PubMed ID: 32280210
[TBL] [Abstract][Full Text] [Related]
9. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
11. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells.
Zhao N; You J; Zeng Z; Li C; Zu Y
Small; 2013 Oct; 9(20):3477-84. PubMed ID: 23609964
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
Tsuyama N; Sakamoto K; Sakata S; Dobashi A; Takeuchi K
J Clin Exp Hematop; 2017; 57(3):120-142. PubMed ID: 29279550
[TBL] [Abstract][Full Text] [Related]
14. A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics.
Zhang L; Wang M; Zhu Z; Chen S; Wu H; Yang Y; Che F; Li Q; Li H
Mol Ther Nucleic Acids; 2021 Dec; 26():732-748. PubMed ID: 34703655
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
16. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
[TBL] [Abstract][Full Text] [Related]
17. Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer.
Wan Q; Zeng Z; Qi J; Chen Z; Liu X; Zu Y
Mol Ther; 2022 Jun; 30(6):2242-2256. PubMed ID: 35143958
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.
Molavi O; Xiong XB; Douglas D; Kneteman N; Nagata S; Pastan I; Chu Q; Lavasanifar A; Lai R
Biomaterials; 2013 Nov; 34(34):8718-8725. PubMed ID: 23942212
[TBL] [Abstract][Full Text] [Related]
19. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
Wang X; Wu J; Zhang M
Hematology; 2019 Dec; 24(1):440-445. PubMed ID: 31072226
[TBL] [Abstract][Full Text] [Related]
20. Caspase-3 activation in systemic anaplastic large-cell lymphoma.
Drakos E; Rassidakis GZ; Lai R; Herling M; O'Connor SL; Schmitt-Graeff A; McDonnell TJ; Medeiros LJ
Mod Pathol; 2004 Jan; 17(1):109-16. PubMed ID: 14657946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
